Clovis Oncology (CLVS) director Azelby received 42,223 Stock Option (right to buy)
Stocks in this Quantisnow insightHealth Care
Insider transactions reported
Robert Azelby (director at Clovis Oncology Inc., CLVS) reported that they received 42,223 Stock Option (right to buy) on Jun 10, 2021.
- Reporting person
- Azelby Robert
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jun 10, 2021 | Grant or award (A) | Stock Option (right to buy)On 42,223 Common Stock1 | +42,223 | - | - | 42,223 direct |
Holdings before and after
- Stock Option (right to buy): 0 to 42,223 direct
Footnotes from the filing
- 1. The options shall vest on the one-year anniversary of the date of grant.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Azelby report in this CLVS Form 4?
Robert Azelby (director at Clovis Oncology Inc., CLVS) reported that they received 42,223 Stock Option (right to buy) on Jun 10, 2021.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for CLVS
Earlier insider filings at CLVS
- Jun 12, 2021SEC Form 4 filed by KLINGENSTEIN PAUL H
- Jun 12, 2021SEC Form 4 filed by BLAIR JAMES C
- Jun 12, 2021SEC Form 4 filed by Flaherty Keith T.
- Jun 12, 2021SEC Form 4 filed by McKinley Edward J
- Jun 12, 2021SEC Form 4 filed by GRAHAM GINGER L
Quantisnow market dataNASDAQ
CLVS
Clovis Oncology Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2011
Get push alerts for CLVS
Full CLVS profile on Quantisnow Follow CLVS and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time